In summary, I have used the case of TCE exposure as an example of: (1) The importance of population-based research to identify and characterize possible environmental risk factors for cancer, and the need for a greater emphasis and proportional increase in public funding of research on prevention as compared to treatment. We need to understand these risks better, and use this information to drive effective public health prevention actions. (2) The imposition of strong restrictions on requests by bona fide researchers for access to data as a barrier to research that could be used to help resolve some of the most controversial issues in TCE epidemiology, in particular, and environmental risks in general, especially access to individual level data including data of event and location of residence. Researchers need ready access these data to more accurately characterize environmental exposures, diseases and their possible associations, and to help develop more effective public health preventive actions, although they should also protect confidentiality. (3) The need for more accurate and comprehensive biomarkers of exposure and disease to better assess possible associations between environmental and occupational exposures and disease; (4) The role of non-scientific concerns in limiting regulatory and advisory agencies in the reevaluation of their positions relative to preventing or lowering allowable exposures to TCE, in light of the growing body of evidence on the possible carcinogenicity of a compound still widely in use, to which many workers, and substantial segments of the general public, are exposed.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4027958 | PMC |
http://dx.doi.org/10.1515/reveh.2009.24.4.297 | DOI Listing |
JCO Glob Oncol
January 2025
Department of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN.
Purpose: The academic field of global pediatric oncology is expanding as cancer becomes increasingly recognized as a global health priority for children and adolescents. Here, we aimed to explore the representation of authors, the geographic distribution of research, and the research approaches being used in global pediatric oncology.
Methods: Articles published in () and on the topic of global pediatric oncology were analyzed.
JCO Glob Oncol
January 2025
Adults Solid Tumors Chemotherapy Department, Yeolyan Hematology and Oncology Center, Yerevan, Armenia.
Purpose: Pancreatic cancer is one of the deadliest cancers in the world. In Armenia, it is 12th by incidence. The aim of this study is to evaluate treatment and outcomes of pancreatic cancer in Armenia during the past 12 years.
View Article and Find Full Text PDFJ Clin Oncol
January 2025
German Breast Group, Neu-Isenburg, Germany.
Purpose: To assess trial-level surrogacy value for overall survival (OS) of the pathologic complete response (pCR) and invasive disease-free survival (iDFS) in randomized clinical trials (RCTs) for early breast cancer (BC).
Methods: Individual patient data of neoadjuvant RCTs with available data on pCR, iDFS, and OS were included in the analysis. We used the coefficient of determination from weighted linear regression models to quantify the association between treatment effects on OS and on the surrogate end points.
ACS Appl Mater Interfaces
January 2025
Department of Urology/State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Sonodynamic therapy, a treatment modality recently widely used, is capable of disrupting the tumor microenvironment by inducing immunogenic cell death (ICD) and enhancing antitumor immunity during immunotherapy. Erdafitinib, an inhibitor of the fibroblast growth factor receptor, has demonstrated potential benefits for treating bladder cancer. However, Erdafitinib shows effectiveness in only a small number of patients, and the majority of patients responding positively to the medication have "immune-cold" tumors.
View Article and Find Full Text PDFPLoS One
January 2025
Institute of Translational Medicine, Medical College, Yangzhou University, Yangzhou, Jiangsu, PR. China.
Objectives: The aim of this study was to develop and validate a nomogram model that predicts the risk of bone metastasis (BM) in a prostate cancer (PCa) population.
Methods: We retrospectively collected and analyzed the clinical data of patients with pathologic diagnosis of PCa from January 1, 2013 to December 31, 2022 in two hospitals in Yangzhou, China. Patients from the Affiliated Hospital of Yangzhou University were divided into a training set and patients from the Affiliated Clinical College of Traditional Chinese Medicine of Yangzhou University were divided into a validation set.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!